Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models

REFERENCES

• Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006; 580: 5533–5540
   PubMed Web of Science ®Google Scholar
• Anderson T. W. An Introduction to Multivariate Statistical Analysis, Second Edition, , et al. John Wiley and Sons, Inc., New York 1984
   Google Scholar
• Bailey A. B., Chanderbhan R., Collazo-Braier N., Cheeseman M. A., Twaroski M. L. The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol. 2005; 42: 225–235
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S., Klaunig J. E., Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology 1990; 12: 48–58
   PubMed Web of Science ®Google Scholar
• Baronas E. T., Lee J. W., Alden C., Hsieh F. Y. Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol. 2007; 218: 72–78
   PubMed Web of Science ®Google Scholar
• Barone L., Small B. G., Valentin J.-P., Pollard C. E., Ciaccio P. J. A comparison between compound potency in an in vitro phospholipidosis assay and at the hERG-encoded potassium channel, Poster. , et al. Society of Toxicology Meeting, Charlotte, NC 2007
   Google Scholar
• Brown W. J., Sullivan T. R., Greenspan P. Histochem. 1992; 97: 349–354
   Google Scholar
• Contrera J. F., Hall L. H., Kier L. B., MacLaughlin P. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Technol. 2005a; 2: 55–67
   PubMedGoogle Scholar
• Contrera J. F., Kruhlak N. L., Matthews E. J., Benz R. D. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Regul. Toxicol. Pharmacol. 2005b; 43: 313–323
   PubMed Web of Science ®Google Scholar
• Contrera J. F., Kruhlak N. L., Matthews E. J., Benz R. D. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul. Toxicol. Pharmacol. 2007; 49: 172–182
   PubMed Web of Science ®Google Scholar
• Contrera J. F., Matthews E. J., Benz R. D. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 2003; 38: 243–259
   PubMed Web of Science ®Google Scholar
• Cooper J. A., Saracci R., Cole P. Describing the validity of carcinogen screening tests. Br. J. Cancer 1979; 39: 87–89
   PubMed Web of Science ®Google Scholar
• Delaney J., Neville W. A., Swain A., Miles A., Leonard M. S., Waterfield C. J. Phenylacetylglicine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers 2004; 9: 271–290
   PubMed Web of Science ®Google Scholar
• Dieterle F., Ross A., Schlotterbeck G., Senn H. Metabolite projection analysis for fast identification of metabolites in metabonomics. Application in an amiodarone study. Anal. Chem. 2006; 78: 3551–3561
   PubMed Web of Science ®Google Scholar
• Grabner R. Influence of cationic amphiphilic drugs on the phosphatidylcholine hydrolysis by phospholipase A2. Biochem. Pharmacol. 1987; 36: 1063–1067
   PubMed Web of Science ®Google Scholar
• Greene N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 2002; 54: 417–431
   PubMed Web of Science ®Google Scholar
• Gum R. J., Hickman D., Fagerland J. A., Heindel M. A., Gagne G. D., Schmidt J. M., Michaelides M. R., Davidsen S. K., Ulrich R. G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 2001; 62: 1661–1673
   PubMed Web of Science ®Google Scholar
• Hall L. H. A structure-information approach to prediction of biological activities and properties. Chem. Biodiversity 2004; 1: 183–201
   PubMed Web of Science ®Google Scholar
• Hall L. H., Kier L. B. Electrotopological state indices for atom types: a novel combination of electronic, topological and valence state information. J. Chem. Inf. Comput. Sci. 1995; 35: 1039–1045
   Google Scholar
• Hall L. H., Kier L. B. Molecular connectivity indices for database analysis and structure-property modeling. Topological Indices and Related Descriptors in QSAR and QSPR, P. Devillers, A. T. Balaban. Gordon and Breach Science Publishers, The Netherlands 1999; 307–360
   Google Scholar
• Hall L. H., Kier L. B. Issues in the representation of molecular structure: the development of molecular connectivity. J. Molec. Graph. Model 2001; 20: 4–18
   PubMed Web of Science ®Google Scholar
• Halliwell W. H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997; 25: 53–60
   PubMed Web of Science ®Google Scholar
• Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 1984; 55: 53–76
   PubMed Web of Science ®Google Scholar
• Ibrahim S., Langhendries J. P., Bernard A., Tulkens P. M. Urinary phospholipids excretion in neonates treated with amikacin. Int. J. Clin. Pharm. Res. 1994; 14: 149–156
   PubMedGoogle Scholar
• Johnson D. E., Rodgers A. D. Computational toxicology: heading toward more relevance in drug discovery and development. Curr. Opin. Drug Discov. Devel. 2006; 9: 29–37
   PubMed Web of Science ®Google Scholar
• Kendall M. G., Stuart A., Ord J. K. The Advanced Theory of Statistics, Vol. 3, , et al. Fourth Edition, Macmillan Publishing Co., Inc., New York 1983
   Google Scholar
• Kodavanti U. P., Mehendale H. M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 1990; 42: 327–354
   PubMed Web of Science ®Google Scholar
• Kruhlak N. L., Contrera J. F., Benz R. D., Matthews E. J. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv. Drug Deliv. Rev. 2007; 59: 43–55
   PubMed Web of Science ®Google Scholar
• Kubo M., Hostetler K. Y. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry 1985; 24: 6515–6520
   PubMed Web of Science ®Google Scholar
• Kunze H., Loffler B. M. Acid phospholipase A1 in liver—a brief survey. Klin. Wochenschr. 1989; 67: 126–130
   PubMedGoogle Scholar
• Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001; 46: 3–26
   PubMed Web of Science ®Google Scholar
• Lüllmann H., Lüllmann-Rauch R., Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 1978; 27: 1103–1108
   PubMed Web of Science ®Google Scholar
• Matthews E. J., Contrera J. F. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul. Toxicol. Pharmacol. 1998; 28: 242–264
   PubMed Web of Science ®Google Scholar
• Matthews E. J., Kruhlak N. L., Benz R. D., Contrera J. F. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr. Drug Discov. Technol. 2004; 1: 61–76
   PubMedGoogle Scholar
• Matthews E. J., Kruhlak N. L., Benz R. D., Ivanov J., Klopman G., Contrera J. F. A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. Regul. Toxicol. Pharmacol. 2007; 47: 136–155
   PubMed Web of Science ®Google Scholar
• Matthews E. J., Kruhlak N. L., Cimino M. C., Benz R. D., Contrera J. F. Analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul. Toxicol. Pharmacol. 2006; 44: 97–110
   PubMed Web of Science ®Google Scholar
• Morelli J. K., Buehrle M., Pognan F., Barone L. R., Fieles W., Ciaccio P. J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 2006; 22: 15–27
   PubMed Web of Science ®Google Scholar
• Mortuza G. B., Nebille W. A., Delaney J., Waterfield C. J., Camilleri P. Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim. Biophys. Acta 2003; 1631: 136–146
   PubMed Web of Science ®Google Scholar
• Nassogne M. C., Lizarraga C., N'Kuli F., Van Bambeke F., Van Binst R., Wallemacq P., Tulkens P. M., Mingeot-Leclercq M. P., Levade T., Courtoy P. J. Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicol. Appl. Pharmacol. 2004; 194: 101–110
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. ChemIDplus Advanced. Online database. 2007, http://chem.sis.nlm.nih.gov/chemidplus/. Accessed July 2007.
   Google Scholar
• Nelson A. A., Fitzhugh O. G. Chloroquine (SN-7618). Pathological changes observed in rats which for two years had been fed various proportions. Arch. Pathol. 1948; 45: 454–462
   PubMedGoogle Scholar
• Organisation for Economic Cooperation and Development (OECD). The report from the expert group on (quantitative) structure-activity relationships [(Q)SARs] on the principles for the validation of (Q)SARs. No. 49. ENV/JM/MONO(2004)24. Organisation for Economic Cooperation and Development. Paris 2004
   Google Scholar
• Pelletier D. J., Gehlhaar D., Tilloy-Ellul A., Johnson T. O., Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 2007; 47: 1196–1205
   PubMed Web of Science ®Google Scholar
• Ploemen J. P., Kelder J., Hafmans T., van de Sandt H., van Burgsteden J. A., Saleminki P. J., van Esch E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. 2004; 55: 347–355
   PubMed Web of Science ®Google Scholar
• Reasor M. J., Hastings K. L., Ulrich R. G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006; 5: 567–583
   PubMed Web of Science ®Google Scholar
• Reasor M. J., Heyneman C. A., Walker E. R. Chlorcyclizine-induced pulmonary phospholipidosis in rats. Res. Comm. Chem. Pathol. Pharmacol. 1982; 38: 235–246
   PubMedGoogle Scholar
• Richard A. M., Gold L. S., Nicklaus M. C. Chemical structure indexing of toxicity data on the internet: moving toward a flat world. Curr. Opin. Drug Discov. Devel. 2006; 9: 314–325
   PubMed Web of Science ®Google Scholar
• Sawada H., Takami K., Asahi S. A. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005; 83: 282–292
   PubMed Web of Science ®Google Scholar
• Seydel J. K., Wassermann O. NMR-studies on the molecular basis of drug-induced phospholipidosis—II. Interaction between several amphiphilic drugs and phospholipids. Biochem. Pharmacol. 1976; 25: 2357–2364
   PubMed Web of Science ®Google Scholar
• Six D. A., Dennis E. A. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochem. Biophys. Acta. 2000; 1488: 1–19
   PubMed Web of Science ®Google Scholar
• Tomizawa K., Sugano K., Yamada H., Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 2006; 31: 315–324
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. White paper. 2004, http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. Accessed July 2007
   Google Scholar
• Wagner P. M., Nabholz J. V., Kent R. J. The new chemicals process at the Environmental Protection Agency (EPA): structure-activity relationships for hazard identification and risk assessment. Toxicol. Lett. 1995; 79: 67–73
   PubMed Web of Science ®Google Scholar
• Wang X., Phelan S. A., Forsman-Semb K., Taylor E. F., Petros C., Brown A., Lerner C. P., Paigen B. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J. Biol. Chem. 2003; 278: 25179–25190
   PubMed Web of Science ®Google Scholar
• Waring J. F., Cavet G., Jolly R. A., McDowell J., Dai H., Ciurlionis R., Zhang C., Stoughton R., Lum P., Ferguson A., Roberts C. J., Ulrich R. G. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. Environ. Health Perspect. Toxicogenomics 2003; 111: 53–60
   PubMed Web of Science ®Google Scholar
• Yang C., Benz R. D., Cheeseman M. A. Landscape of current toxicity databases and database standards. Curr. Opin. Drug Discov. Devel. 2006; 9: 124–133
   PubMed Web of Science ®Google Scholar
• Zeeman M., Auer C. M., Clements R. G., Nabholz J. V., Boethling R. S. U.S. EPA regulatory perspectives on the use of (Q)SAR for new and existing chemical evaluations. SAR QSAR Environ. Res. 1995; 3: 179–201
   PubMedGoogle Scholar